Literature DB >> 1375508

Antifibrinolytic activities of alpha-N-acetyl-L-lysine methyl ester, epsilon-aminocaproic acid, and tranexamic acid. Importance of kringle interactions and active site inhibition.

P K Anonick1, J Vasudevan, S L Gonias.   

Abstract

alpha-N-acetyl-L-lysine methyl ester (NALME) is a lysine analogue that reportedly binds to low-affinity lysine binding sites in plasmin(ogen) and miniplasmin(ogen). In the studies presented here, we show that NALME has antifibrinolytic activity; however, unlike the therapeutic agents epsilon-amino-n-caproic acid (epsilon ACA) and tranexamic acid (TEA), the activity of NALME is based on inhibition of the plasmin active site. NALME (0.1-10 mM) significantly inhibited the amidase activity of plasmin, miniplasmin, and streptokinase-plasmin complex without affecting alpha-thrombin or tissue plasminogen activator. epsilon ACA and TEA (0.1-10 mM) did not affect the amidase activity of plasmin or miniplasmin. A kinetic analysis showed that NALME is a competitive inhibitor of D-Val-L-Lys-p-nitroanilide HCl (S-2251) hydrolysis by plasmin; NALME binding to plasmin completely prevented S-2251 binding. The Kl for the plasmin-NALME interaction was 0.4 mM. epsilon ACA and TEA inhibited fibrin monomer digestion by plasmin and miniplasmin without binding to the active site of either enzyme. This result suggests that epsilon ACA and TEA function as antifibrinolytics by disrupting the noncovalent association of fibrin monomer with a domain common to both plasmin and miniplasmin (probably kringle 5). NALME inhibited fibrin monomer digestion principally by decreasing amidase activity. NALME was the only lysine analogue that prevented fragment X formation; TEA and epsilon ACA primarily inhibited the formation of fragments Y and D. When plasmin was incubated simultaneously with alpha 2-antiplasmin and alpha 2-macroglobulin, epsilon ACA increased the fraction of plasmin reacting with alpha 2-macroglobulin; NALME had no effect on the plasmin distribution.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375508     DOI: 10.1161/01.atv.12.6.708

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  10 in total

1.  Fibrin degradation enhances vascular smooth muscle cell proliferation and matrix deposition in fibrin-based tissue constructs fabricated in vitro.

Authors:  Katherine A Ahmann; Justin S Weinbaum; Sandra L Johnson; Robert T Tranquillo
Journal:  Tissue Eng Part A       Date:  2010-10       Impact factor: 3.845

2.  Fabrication of 3-dimensional multicellular microvascular structures.

Authors:  Sebastian F Barreto-Ortiz; Jamie Fradkin; Joon Eoh; Jacqueline Trivero; Matthew Davenport; Brian Ginn; Hai-Quan Mao; Sharon Gerecht
Journal:  FASEB J       Date:  2015-04-21       Impact factor: 5.191

Review 3.  Tranexamic acid: a review of its use in surgery and other indications.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 4.  Tranexamic acid: a review of its use in the management of menorrhagia.

Authors:  Keri Wellington; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Characterization of the antiplasmin activity of human thrombospondin-1 in solution.

Authors:  P K Anonick; J K Yoo; D J Webb; S L Gonias
Journal:  Biochem J       Date:  1993-02-01       Impact factor: 3.857

Review 6.  Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

7.  Interaction between Borrelia miyamotoi variable major proteins Vlp15/16 and Vlp18 with plasminogen and complement.

Authors:  Frederik L Schmidt; Valerie Sürth; Tim K Berg; Yi-Pin Lin; Joppe W Hovius; Peter Kraiczy
Journal:  Sci Rep       Date:  2021-03-02       Impact factor: 4.379

8.  The degradation of gelatin/alginate/fibrin hydrogels is cell type dependent and can be modulated by targeting fibrinolysis.

Authors:  Elea Boucard; Luciano Vidal; Flora Coulon; Carlos Mota; Jean-Yves Hascoët; Franck Halary
Journal:  Front Bioeng Biotechnol       Date:  2022-07-22

Review 9.  Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  Med Res Rev       Date:  2014-03-21       Impact factor: 12.944

10.  Tranexamic acid blocks the thrombin-mediated delay of epidermal permeability barrier recovery induced by the cedar pollen allergen, Cry j1.

Authors:  S Nakanishi; J Kumamoto; M Denda
Journal:  Sci Rep       Date:  2018-10-23       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.